Loading…
Employees: 152
Size Allogene Therapeutics (ALLO) is a United States Health Care company (Biotechnology) with a market value of $359M, the 2957th largest of 3,117 United States companies the cockpit tracks. Shares closed at $1.04 on 6 Nov 2026.
Performance Over six months the shares fell 54.4%, against -27.8% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median -3.5%); the operating margin is -3,886.1% (peer median -336.8%).
Valuation It trades at 22.8× enterprise value to sales against a peer median of 10.7× (7th most expensive of 15).
Capital Return on invested capital runs 86.1 points below its cost of capital (8.1% WACC).
Short interest Short interest is 15.5% of the free float (15 Oct 2026).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $4.64M | $0 | $22,000 | $95,000 | $156,000 |
| Revenue growth | — | -100% | -77% | -39% | — |
| Gross profit | -$7.03M | -$12.4M | -$13.6M | -$14.1M | -$14.1M |
| EBITDA | -$169M | -$195M | -$244M | -$300M | -$321M |
| Net income | -$165M | -$191M | -$258M | -$327M | -$340M |
| Free cash flow | -$103M | -$150M | -$201M | -$239M | -$226M |
| Capital expenditure | $402,000 | $386,000 | $694,000 | $1.52M | $5.19M |
| Total debt | $79.0M | $83.3M | $90.8M | $95.1M | $101M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALLO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.7% | -13.5% | 7th lowest of 20 |
| 6-month return | -54.4% | -27.8% | 3rd lowest of 19 |
| Distance from 52-week high | -76.7% | -52.5% | 3rd lowest of 20 |
| Revenue growth (TTM) | -100.0% | -3.5% | 2nd lowest of 16 |
| Operating margin | -3,886.1% | -336.8% | 3rd lowest of 15 |
| EV / Sales | 22.8× | 10.7× | 7th most expensive of 15 |
| ROIC minus cost of capital | -86.1 pp | -25.4 pp | 4th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | 7.1× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | 14.4× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |